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Abstract
Microenvironmental conditions such as hypoxia potentiate the local invasion of malignant tumors including glio-
blastomas by modulating signal transduction and protein modification, yet the mechanism by which hypoxia
controls cytoskeletal dynamics to promote the local invasion is not well defined. Here, we show that cyclin G2
plays pivotal roles in the cytoskeletal dynamics in hypoxia-driven invasion by glioblastoma cells. Cyclin G2 is a
hypoxia-induced and cytoskeleton-associated protein and is required for glioblastoma expansion. Mechanistically,
cyclin G2 recruits cortactin to the juxtamembrane through its SH3 domain–binding motif and consequently promotes
the restricted tyrosine phosphorylation of cortactin in concert with src. Moreover, cyclin G2 interacts with filamentous
actin to facilitate the formation of membrane ruffles. In primary glioblastoma, cyclin G2 is abundantly expressed
in severely hypoxic regions such as pseudopalisades, which consist of actively migrating glioma cells. Furthermore,
we show the effectiveness of dasatinib against hypoxia-driven, cyclin G2–involved invasion in vitro and in vivo.
Our findings elucidate the mechanism of cytoskeletal regulation by which severe hypoxia promotes the local invasion
and may provide a therapeutic target in glioblastoma.
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Introduction
Glioblastoma multiforme (GBM), the most common and malignant
primary tumor arising in the central nervous system, is characterized
by a variety of pathologic findings including vascular proliferation,
aggressive invasion, and pseudopalisades [1], which are promoted
by hypoxic conditions [2,3]. Pseudopalisades consist of necrotic foci
and surrounding glioma cells and are a specific finding that distin-
guishes GBM from lower grade astrocytomas [4]. They were also
shown to consist of hypoxic and actively migrating glioma cells [5].
In the expansion of GBM, hypoxia contributes to the maintenance
of glioma stem cells, angiogenesis, and cellular migration through the
accumulation of hypoxia-inducible factor 1α (HIF-1α) and conse-
quent activation of several genes [6–8]. Studies using microarray-
based gene expression profiling in glioma or neuroblastoma cells have
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indicated the knockdown of HIF-1α to result in reduced expression of
ccng2 mRNA (which encodes cyclin G2), suggesting that cyclin G2
expression is hypoxia-responsive [9–11]. Cyclin G2 was first iden-
tified as a negative regulator of cell cycle progression [12] and shown
to bind to an active complex of protein phosphatase 2A (PP2A) and
induce a p53-dependent cell cycle arrest [13]. Moreover, cyclin G2
interacts with and stabilizes microtubules, suggesting that cyclin G2
contributes to the regulation of cytoskeletal dynamics [13]. Despite
evidence that the expression and subcellular distribution of cyclin G2
were related to epithelial cancer progression and metastasis [14–16],
the precise mechanism by which cyclin G2 controls tumor expansion
is unclear, especially in GBM.
Although several studies have shown that hypoxia induced by tumor
enlargement or antiangiogenic therapy stimulated the local invasion of
glioblastoma cells by modulating signal transduction [8], we do not
have sufficient evidence that hypoxia regulates cytoskeletal dynamics,
which is required for cellular motility, to promote the local invasion
of glioblastoma. Accordingly, the aim of this study is to elucidate the
precise mechanism of cytoskeletal regulation in the hypoxia-driven
invasion and thereby provide evidence of a therapeutic strategy in
glioblastoma. Especially, we here focus on the roles of cyclin G2 in
cellular migration in response to hypoxia from the viewpoint of cyto-
skeletal regulation.
Materials and Methods
Cell Culture and Reagents
Human glioma cell lines U87MG, U251MG, and LNZ308 and
human embryonic kidney (HEK) 293 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% FBS and penicillin/
streptomycin (Life Technologies, Carlsbad, CA). Murine glioma-
initiating 005 cells were cultured as previously reported [17]. For hyp-
oxic stimulation, cells were cultured in medium containing 100 μM
deferoxamine mesylate (Sigma-Aldrich, St Louis, MO) or hypoxic
chamber maintained at 5% or 1% O2. For the analysis of tyrosine
phosphorylation, 10 μM erlotinib (LKT Laboratories, Inc, St Paul,
MN) or 1 μM dasatinib (Selleck Chemicals, Houston, TX) was added
before the hypoxic stimulation (Figure W7).
For the immunoblot analysis, the following antibodies were used as
the primary antibody: anti–cyclinG2, anti-Src, anti-p21, anti-p53, anti-
green fluorescent protein (GFP; Santa Cruz Biotechnology, Inc, Dallas,
TX), anti–HIF-1α (Novus Biologicals, LLC, Littleton, CO), anti–α-
tubulin, anti–β-actin (Sigma-Aldrich), anti-cortactin, anti-phosphotyrosine
(Millipore, Billerica, MA), and anti-Src (Cell Signaling Technology,
Inc, Danvers, MA). For the immunohistochemistry and immuno-
fluorescence, the following antibodies were used: anti–cyclin G2, anti-
Src, anti-CD68 (Santa Cruz Biotechnology, Inc), anti–HIF-1α (Novus
Biologicals, LLC), anti-human glial fibrillary acidic protein (GFAP),
anti-cortactin (Abcam, Cambridge, United Kingdom), anti–α-tubulin
(Sigma-Aldrich), anti-cortactin, anti-phosphotyrosine (Millipore),
and anti–phospho-Src (Y417) (Life Technologies). Alexa Fluor 555–
conjugated phalloidin and Hoechst (Life Technologies) were used for
the detection of F-actin and nuclei, respectively. Validation of the use
of the cyclin G2 antibody in immunoblot, immunofluorescent, and
immunostaining analyses was reported in the past studies [14,18,19]
and was further confirmed as shown in Figure W7.
For the analysis of cell proliferation and viability, the water soluble
tetrazolium-1 (WST-1) assay was performed according to the man-
ufacturer’s protocol (Roche, Tokyo, Japan).
Luciferase Reporter Assay
The human cyclin G2 promoter region (−1600∼0) was amplified
from genomic DNA of U87MG cells and cloned into a pGL4.14
luciferase reporter vector (Promega, Madison, WI). The vectors were
transfected into U87MG cells before hypoxic stimulation and cul-
tured in a hypoxic chamber for 24 hours. The cells were lysed and
incubated with the Luciferase Assay System (Promega) before mea-
surements were made. Oligonucleotides for amplification of human
cyclin G2 promoter region were given as follows: forward, 5′-
CAAAACCCTCACCAAGCTCACACCTCTCTG-3′; reverse, 5′-
CCCCTTGTTTTTGTTAAGAGTTTCGACGCC-3′.
Wound-Healing Assay
Cells were plated on Matrigel-coated glass slips at 90% confluence
and cultured for 24 hours in DMEM with 10% FBS. The next day,
the slips were scratched with white tips (200 μl), and the medium
was switched to DMEM with 0.1% FBS. Then, the cells were incu-
bated in normoxic or hypoxic conditions for 24 hours and observed.
To examine the effects of ectopic expression of cyclin G2 on cellular
motility, plasmids encoding cyclin G2–enhanced green fluorescent
protein (EGFP), EGFP, G2K219Q-EGFP, or G2P291A-EGFP were
transfected before the scratching.
Plasmids, Small Interfering RNA, and Retroviruses
The human cyclin G2 cDNA was purchased from OriGene
(Rockville, MD; Cat. No. SC117452), and the open reading frame
was cloned into a pEGFP-N3 (Clontech, Mountain View, CA) or a
pcDNA3.1/V5-His TOPO vector (Life Technologies). The K219Q
and P291A mutants were generated using the site-directed mutagen-
esis kit (Stratagene, La Jolla, CA). Small interfering RNA (siRNA) and
scrambled RNA were obtained from Thermo Fisher Scientific Inc
(Waltham, MA; Dharmacon, ON-TARGETplus siRNA Reagents).
The retrovirus encoding scrambled shRNA or shRNA against human
ccng2 was prepared using the HuSH-29 plasmids (OriGene) and PT67
cells (Clontech) according to the manufacturer’s recommendation.
RNA Purification, cDNA Synthesis, and Real-Time Reverse
Transcription–Polymerase Chain Reaction
For reverse transcription–polymerase chain reaction (PCR) analy-
sis, total RNA was isolated from GBM and cancer cells using an
RNeasy kit (Qiagen, Santa Clarita, CA) and subjected to on-column
digestion of genomic DNA with RNase-free DNase (TaKaRa, Otsu,
Japan). With 1 μg of purified total RNA, cDNA was synthesized
using a Maxima cDNA synthesis kit (Thermo Fisher Scientific
Inc) Quantitative analyses of CCNG2, FYN, CSK, SRC, LYN, and
LCK mRNA were performed with RT2 SYBR Green master mixes
(Qiagen) and the ABI PRISM 7000 Sequence Detection System
(Life Technologies). As an internal control, the copy number of
ACTB (β-actin) mRNA was determined. We obtained predesigned
and certified primers from TaKaRa. All data were analyzed using
software (7000v1.1; Life Technologies).
Western Blot Analysis and Preparation of Cytoskeletal Pellets
Immunoblot analysis was performed as described previously [20].
Cells were lysed in cell lysis buffer [20mMTris-HCl (pH7.5), 150mM
NaCl, 1 mM EDTA, 1 mM EGTA, and 0.5% Triton X-100) contain-
ing Complete Proteinase Inhibitor Cocktail (Roche). For the detection
of phosphoprotein, PhosSTOP Phosphatase Inhibitor Cocktail (Roche)
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was added. Samples were subjected to sodium dodecyl sulfate (SDS)–
polyacrylamide gel electrophoresis, blotted on a nitrocellulose mem-
brane, and subjected to immunodetection. HRP signals were visualized
using Chemiluminescent Peroxidase Substrates (Sigma-Aldrich) and
detected by VersaDoc (Bio-Rad, Hercules, CA). Signal density was
analyzed using the VersaDoc software. All raw data are shown in
Figure W8.
For preparing a cytoskeletal fraction mainly containing filamentous
actin, we used a G-actin/F-actin In Vivo Assay Biochem Kit (Cyto-
skeleton, Inc) with minor modifications. Briefly, EGFP-, cyclin G2–
EGFP–, or G2K219Q-EGFP–transfected U87MG cells were incubated
with phalloidin (1 μg/ml) and nocodazole (200 ng/ml) for 2 hours
before the fractionation of filamentous actin with the kit. For themicro-
tubule pellet, the cells were incubated with latrunculin B (250 ng/ml)
and paclitaxel (500 ng/ml) for 2 hours and lysed with microtubule
stabilization buffer [50mMPipes (pH6.9), 5mMMgCl2, 2mMEGTA,
0.1%TritonX-100, 0.1%NP-40, 100 μMGTP, 1mMATP, 250 ng/ml
latrunculin B, 500 ng/ml paclitaxel] before fractionation by ultra-
centrifuge (100,000g).
Immunohistochemistry and Immunofluorescence
Paraffin-embedded human GBM specimens were prepared in the
Okayama University Hospital’s Department of Pathology. Sections
were deparaffinized, epitope-retrieved with proteinase XXV (Thermo
Scientific), and blocked with 5% donkey serum in phosphate-
buffered saline (Abcam). Slides were incubated at 4°C for 16 hours
with primary antibodies, visualized with the ImmPRESS polymerized
enzyme staining kit (VECTOR Laboratories, Burlingame, CA), and
counterstained with hematoxylin. For the immunofluorescent analy-
sis of human GBM specimens, sections were prepared as described
above except for the secondary antibodies (Life Technologies; Alexa
Fluor 488– or Alexa Fluor 555–conjugated antibodies). For the
immunofluorescent analyses of glioma cell lines, cells were fixed with
4% paraformaldehyde (PFA) for 15 minutes, permeated with 0.2%
Triton X-100 for 10 minutes, and blocked with 5% goat (Abcam)
or donkey serum. The samples were then incubated with primary
antibodies and secondary antibodies. Immunofluorescent samples
were observed with a confocal laser scanning microscope (FluoView
300; Olympus, Tokyo, Japan).
Immunoprecipitation and Chromatin Immunoprecipitation Assay
To investigate the interaction between cyclin G2, cortactin, and
src family kinases (SFKs), plasmids encoding EGFP, EGFP-tagged
cyclin G2, or the EGFP-tagged cyclin G2 mutant were transfected
into U87MG cells using Lipofectamine 2000 according to the manu-
facturer’s instructions (Life Technologies). After 20 hours, cells were
lysed with immunoprecipitation (IP) buffer [20 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 1% Triton X-100, and proteinase inhib-
itor cocktail] and centrifuged. The supernatant was precleaned with
protein G sepharose, incubated with anti-GFP antibody, and precip-
itated with protein G sepharose. Precipitated samples were boiled in
2× SDS buffer. For detection of phosphotyrosine, hypoxia-stimulated
or cyclin G2–transfected U87MG cells were lysed in IP buffer
containing PhosSTOP (Roche) and immunoprecipitated with anti-
cortactin antibody.
For chromatin immunoprecipitation (ChIP) assay, 5 × 107 U87MG
cells (cultured in normoxic or hypoxic conditions for 24 hours) were
incubated with formaldehyde (final concentration of 0.75%) at room
temperature for 15 minutes and lysed with lysis buffer [50 mM Hepes
(pH 7.5), 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1%
sodium deoxycholate, 0.1% SDS, protease inhibitor]. After sonication,
DNA concentrations of the samples were determined and the samples
containing 25 μg of DNA were immunoprecipitated with anti–HIF1-α
antibody or control mouse IgG, followed by PCR. Oligonucleotides
for the ChIP assay were given as follows: HIF-1α—forward, 5′-CTCT-
TCCCAGGGACTATCTG-3′; reverse, 5′-GACTGAAGGAGG-
GGCTTTTC-3′.
Statistical Analysis
Data were analyzed either by Student’s t test to identify significant
differences between two groups or by Scheffe’s posttest following a
two-way analysis of variance to compare multiple groups. P values
less than .05 were considered significant.
Results
Cyclin G2: A Marker of Pseudopalisades
To unveil the mechanism by which hypoxia regulates cytoskeletal
dynamics, we first sought hypoxia-induced and cytoskeleton-associated
proteins. According to past microarray studies in glioblastoma [9–11]
and the ELM database analysis [21], we predicted cyclin G2 as a
candidate (Figure W1, A–D). Cyclin G2 expression was commonly
upregulated among three subsets of microarray data in hypoxia-treated
glioblastoma or hypoxic region of GBM, and it was positively correlated
with hypoxia signature (hypoxia-responsive genes, e.g., ANGPTL4 and
HK2) [22,23] also in the other array data set (Figure W1, B and C ); the
ELM program predicted that cyclin G2 had a putative SH2 domain–
binding motif in the N terminus, an actin-interacting WH2 motif, and
an SH3 domain–binding motif in the C terminus (Figure W1D). In
fact, cyclin G2 expression was significantly increased in glioblastoma-
derived cell lines in response to hypoxic stimulations (Figure 1, A and
B). In the human ccng2 (which encodes cyclin G2 protein) promoter
region, we found some putative hypoxia-responsive elements (HREs;
-CGTG-; Figure W2) [24]. Through luciferase reporter assays using
the human ccng2 promoter region and ChIP, we revealed that cyclin
G2 expression was directly regulated by HIF-1α (Figure 1, C and D).
Knockdown of HIF-1α by RNA interference caused a deficit of the
hypoxia-induced cyclin G2 expression (Figure 1E and data not shown).
Interestingly, p53, which affects themalignancy of glioblastoma, had no
relationship to cyclin G2 expression (U87MG, p53WT; U251MG,
p53Mut; LNZ308, p53Null, respectively), and the forced expression of
p53 had no effect on cyclin G2 expression (Figure W3A). In primary
glioblastoma, we detected immunoreactive signals for cyclin G2 in the
cytoplasm of glioma cells, not in inflammatory cells (CD68 positive), in
hypoxic regions such as pseudopalisades, whereas no signal was observed
in high cellularity/mitotic regions (Figures 1, F–R, and W4, A–D).
Cyclin G2 is an unconventional cyclin, which interacts with an
active complex of PP2A and induces cell cycle arrest [12]. Recent
studies indicated cyclin G2 to be involved in the progression of oral
squamous cell carcinoma [14] and breast carcinoma [15,16]. In
breast cancer, cyclin G2 was defined as a marker of suppression of
invasion and metastasis under the control of TAp63, a well-known
regulator of carcinoma expansion. However, the mechanism by
which cyclin G2 determines cellular behavior is completely unclear.
Importantly, cyclin G2 expression is enhanced by a variety of tran-
scriptional molecules such as FoxO3a [25,26], Nodal-ALK4/7 [27],
and HIF-1α (as shown in Figure 1), which are all known as key
promoters of glioblastoma expansion. Combined with our findings
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Figure 1. Cyclin G2 is a hypoxia-induced protein and abundant in pseudopalisade-forming glioma cells. (A and B) Hypoxic conditions
enhance ccng2 mRNA transcription (A) and cyclin G2 protein expression (B). Cells were cultured in normoxic, deferoxamine mesylate
(a reagent to mimic hypoxia)–added, or hypoxic conditions for 24 hours and subjected to reverse transcription–PCR or Western blot
analysis. (C) Luciferase reporter assay with the human ccng2 promoter/pGL4.14 vector. U87MG cells were transfected with the reporter
vector and cultured in normoxic or hypoxic conditions for 24 hours. Bars represent the SD. (D) ChIP assay showing that cyclin G2
expression is directly regulated by HIF-1α. (E) Cyclin G2 expression is dependent on HIF-1α accumulation. Cells treated with siRNA
against HIF-1α show lower expression of cyclin G2 than scrambled siRNA-treated cells under hypoxic conditions. (F–M) Human glio-
blastoma specimens stained with hematoxylin and eosin (H&E) and immunostained with anti–cyclin G2 antibody. Other images are
shown in Figure W4. (N) Cyclin G2 accumulates at the leading edge of glioma cells migrating from the necrotic foci to adjacent tissue.
(O and P) Cyclin G2 is abundant in pseudopalisade-forming glioma cells (O) but not in inflammatory cells (CD68 positive) (P). (Q and R)
Cyclin G2 expression is abundant in hypoxic or near necrotic regions. Dotted lines indicate the borders of pseudopalisades (F–I).
The scale bars represent 200 μm (J–M), 50 μm (N), 100 μm (O and P), respectively. Numbers in B and E represent the ratio of densi-
tometry analysis.
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that cyclin G2 is abundantly expressed in pseudopalisades, which
consist of actively migrating glioma cells [4,5], we assumed that cy-
clin G2 had promotive effects on tumor expansion in glioblastoma,
especially the hypoxia-driven local invasion, unlikely breast cancer.
Cyclin G2 Promotes GBM Migration
To test our hypothesis, we first investigated the role of cyclin G2
in the motility of glioblastoma cells. Wound-healing assays showed
that hypoxia promoted the migration of glioblastoma cells (Fig-
ure 2A). As expected, the ectopically expressed cyclin G2 promoted
migration of U87MG and U251MG cells even under normoxic
conditions (Figure 2, B–E ). To confirm this, we prepared cyclin
G2–reduced U87MG and U251MG cells using a retroviral vector
encoding shRNA against human ccng2 (Figure 2F ). The reduction
in cyclin G2 caused excessive cell proliferation and p21 suppression,
maybe because of the lack of cell cycle–inhibiting potential of cyclin
G2 (Figure W3, B and C ). Moreover, the shRNA-treated U87MG
cells were flat and epithelia-like, unlike the spindle-shaped control
cells (Figure 2G ). Through wound-healing assays and single-cell
tracing, we found that reduced expression of cyclin G2 caused the
decrease in migration and cellular motility (Figure 2, H–J ). In past
studies, antiangiogenic treatment promoted the local invasion of
glioblastoma cells by inducing hypoxic conditions [8]. According to
our findings, cyclin G2 was involved in this. To verify this assump-
tion, we intracranially implanted shRNA-treated U251MG cells
into immunodeficient mice and treated them with CBO-P11, a vas-
cular endothelial growth factor inhibitor. As previously reported [28],
CBO-P11 reduced the cell density of the tumor core but promoted
the local invasion of the cells treated with scrambled shRNA (Figure 2,
K –P ). In contrast, in cyclin G2–reduced U251MG cells, the local
Figure 2. Cyclin G2 promotes glioblastoma cell migration and is required for the hypoxia-driven invasion of glioblastoma. (A) Hypoxia
promotes the migration of glioma cells. (B–E) Wound-healing assay showing that forced expression of cyclin G2 promotes the migration
even under normoxic conditions. The histograms show the number of EGFP-positive migrating cells in cyclin G2–EGFP– or EGFP-
transfected U87MG cells (C) or the filled wounded area in U251MG cells (E). (F) U87MG and U251MG cells were infected with retroviral
vectors encoding shRNA against human ccng2 or scrambled shRNA. (G) A reduction in cyclin G2 expression changes the cell shape
from spindle to flat in U87MG cells. (H–J) Knockdown of cyclin G2 results in reduced wound healing (H) and cellular motility (I). Motile
speed is reduced by almost half (J). (K–S) Antiangiogenic treatment promotes the local invasion of glioblastoma cells in a cyclin
G2–dependent manner. U251MG cells treated with shRNA against ccng2 did not showmigration induced by CBO-P11 treatment. The
scale bars represent 20 μm (G) or 500 μm (K–S).
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invasion did not emerge (Figure 2,Q–S). These findings show that cyclin
G2 is involved in the hypoxia-driven local invasion of glioblastoma.
Cyclin G2 Is a Cytoskeleton-Associated Protein
To examine the molecular mechanism of the cyclin G2–dependent
tumor expansion, we next performed immunofluorescent analyses
to detect the distribution of endogenous and exogenous cyclin G2
in glioma cells. Cyclin G2 occurred in the cytoplasm of U87MG cells
in a normoxic and steady state (Figure 3A). However, under hypoxic
conditions, the endogenous cyclin G2 accumulated at the leading
edge, often referred to as membrane ruffles, merging with actin fila-
ments (Figure 3A). The exogenously expressed cyclin G2–EGFP or
cyclin G2–V5 also showed a peripheral distribution even under nor-
moxic conditions (Figure 3, B and C ). Immunoelectron microscopic
analysis confirmed the co-localization of cyclin G2 and actin filaments
(Figure 3D). In a previous study, cyclin G2 was shown to interact
with microtubules [13]. To further understand the association
between cyclin G2 and the cytoskeleton, we prepared a cytoskeletal
pellet mainly containing actin filaments or microtubules (for details,
see Materials and Methods section). Intriguingly, cyclin G2 was
observed in the pellet under both actin-stabilizing (phalloidin and
nocodazole treatment) and microtubule-stabilizing (latrunculin B
and paclitaxel treatment) conditions (Figure 3E ). On the basis of the
ELM database prediction, cyclin G2 has a putative, actin-interacting
WH2 motif (Figure 3F ). To check whether cyclin G2 interacts with
Figure 3. Cyclin G2 interacts with actin filaments, and the interaction is required for the motility of glioblastoma cells. (A) Endogenous
cyclin G2 (green) localizes at the leading edge of migrating U87MG cells merging with F-actin (red). In hypoxia-stimulated U87MG cells,
endogenous cyclin G2 accumulated at membrane ruffles. (B and C) Exogenously expressed cyclin G2–EGFP (B) and cyclin G2–V5
(C) also localize at the ruffles. (D) Immunoelectron microscopy of U87MG cells transfected with cyclin G2–EGFP. Arrowheads indicate
the immunogold labeling of EGFP. (E) Cyclin G2 interacts with both filamentous actin and microtubules. (F) Cyclin G2 has a putative WH2
motif. (G–I) The K219Q mutant impairs the interaction with actin filaments (G), the potentiation of ruffle formation (H), and the conse-
quent migration (I). Cortactin (blue) served as a marker of membrane ruffles (H). The scale bars represent 50 μm (A, H), 10 μm (B, C),
200 nm (D), or 200 μm (I).
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actin filaments through this motif and affects actin polymerization, we
prepared a K219Qmutant, which lacks the essential lysine in theWH2
motif [29]. In the actin-stabilized pellet, we observed a decreased
signal of the K219Q mutant compared to wild-type cyclin G2, but
total amounts of actin signals in the pellet seemed to be unchanged
(Figure 3G). Moreover, the K219Q mutant lacks the potentiation of
cyclin G2–induced ruffle formation and migration (Figure 3,H and I ).
These findings suggested that cyclin G2 interacted with actin filaments
and affected the cytoskeletal dynamics at the leading edge of migrating
cells using a certain mechanism, not promoting actin polymerization.
Cyclin G2 Promotes the Restricted Tyrosine Phosphorylation
of Cortactin
We investigated the possibility that cyclin G2 might interact with
cortactin and dynamin 2, actin-binding proteins and targets of onco-
gene src kinases [30], because they are well-defined regulators of
actin dynamics and facilitators of ruffle formation, invadopodia for-
mation, and consequent tumor invasion [31–33]. In glioblastoma
cells, cyclin G2 co-localized with actin filaments and cortactin, or
dynamin 2 at ruffles (Figure 4, A and B), and interacts with endog-
enous cortactin and dynamin 2 (Figure 4C ). Notably, cyclin G2’s
reduction impaired cortactin’s recruitment to the juxtamembrane
and ruffle formation triggered by hypoxia (Figure 4, D and E ),
not by affecting cortactin expression levels (Figure 4F ). These obser-
vations led to a hypothesis that enhanced expression of cyclin G2
owing to hypoxia or exogenous treatment influences actin dynamics
and cellular motility by regulating cortactin or dynamin 2 function.
In the regulation of actin dynamics in which cortactin and dynamin
2 are involved, tyrosine phosphorylation of cortactin is essential [34],
and SFKs are required for the phosphorylation and consequent inva-
sion [35]. Therefore, we investigated cortactin or dynamin 2 phos-
phorylation by immunoprecipitation and immunoblot analysis. In
hypoxia-treated U87MG cells, cortactin, but not dynamin 2, was
tyrosine-phosphorylated in an SFK-dependent manner (Figure 4G ).
This phosphorylation was also observed in hypoxic regions, typically
pseudopalisades in glioblastoma specimens (Figure 4H ), and seemed
to be related to the abundance of cyclin G2 (Figure 4I ). Surprisingly,
even under normoxic conditions, the exogenously expressed cyclin
G2 (tagged with EGFP or V5) also induced cortactin phosphorylation
in an SFK-dependent manner (Figure 4, J and K ). Elevated levels of
cyclin G2 did not increase the total amount of tyrosine-phosphorylated
protein (Figure W5A). These results show that abundant cyclin G2
induces the restricted tyrosine phosphorylation of cortactin. This could
be explained by the fact that cyclin G2 was required for the localization
of cortactin to the juxtamembrane, where SFKs phosphorylated cor-
tactin. Ectopic cyclin G2 enhances the peripheral signal of phospho-
tyrosine in an SFK-dependent manner (Figure W5B). Furthermore,
the increased motility by exogenous cyclin G2 as observed in Figure 2,
B to E , was blocked by dasatinib but not erlotinib (Figure 4L).
Although cyclin G2 binds to an active PP2A complex, the tyrosine
phosphorylation of cortactin induced by abundant cyclin G2 was not
influenced by okadaic acid (PP2A inhibitor) or D-erythro-S (PP2A
activator) treatment (Figure 4M).
Cyclin G2 Is an SH3 Domain–Containing Protein that
Provides a Functional Connection of Src, Cortactin,
and Actin Cytoskeleton at the Ruffles
In primary glioblastoma, SFK expression was enhanced in the
glioma cells that also expressed cyclin G2 abundantly (Figure 5A).
In U87MG cells, hypoxic conditions enhanced, whereas ectopic
cyclin G2 did not induce, the expression of fyn and src, which are
effectors of oncogenic epidermal growth factor receptor signals in
glioblastoma [36] (Figures 5B and W5C ). These observations sup-
port our findings above that cyclin G2 promotes cortactin phosphor-
ylation and consequent migration in concert with SFKs, and it may be
appropriate to presume that the hypoxia-induced, excessive expres-
sion of cyclin G2 and SFKs synergistically potentiates the hypoxia-
driven local invasion through the restricted tyrosine phosphorylation
of cortactin.
Next, we examined the biochemical interaction between cyclin G2,
cortactin, and SFKs. These proteins were co-immunoprecipitated
(Figure 5C ). According to the ELM-based prediction that cyclin
G2 has a putative SH2 domain–binding motif and a noncanonical
SH3 domain–binding motif (Figure 5D), we expected the N terminus
of cyclin G2 to be important for cyclin G2–SFK interactions and the
C terminus for cortactin phosphorylation. SH2 domain–containing
proteins such as SFKs target phosphotyrosine-containing peptides
in a sequence-specific manner [37]. As expected, we found that cyclin
G2 was tyrosine-phosphorylated in an SFK-dependent manner
(Figure 5E ) and deletion of the N terminus in cyclin G2 (ΔN-G2)
impaired cyclin G2–Src interaction (Figure 5F ). A past study showed
that a noncanonical SH3 domain–binding motif (PxxPxxP) was
important for interaction with an SH3 domain–containing protein,
cortactin [38]. The G2-P291A mutant (G2P291A, which has a critical
mutation in a noncanonical SH3 domain–binding motif) showed no
interaction with cortactin and the consequent induction of tyrosine
phosphorylation of cortactin and migration (Figures 5, G and H ,
and W5D). The G2P291A mutant did not cause ruffle formation
and the recruitment of cortactin to the juxtamembrane in U87MG
cells (Figure 5, I–N ). Furthermore, to evaluate the effect of dasatinib
on the tumor expansion induced by antiangiogenic treatment, we
intracranially implanted U251MG cells and treated them with
CBO-P11 alone or CBO-P11 plus dasatinib. As expected, dasatinib
efficiently inhibited the expansion of glioma cells induced by CBO-
P11 treatment (Figure 5, O–T ). Combined with the results in
Figure 2, K to S , these findings showed that the cyclin G2–SFKs–
cortactin axis was required for the local invasion induced by hypoxia
or antiangiogenic treatment in vitro and in vivo and the inhibition
of SFKs by dasatinib attenuated it and that cyclin G2 acted upstream
of SFK-cortactin.
Discussion
In summary, we demonstrated that cyclin G2 played pivotal roles in
the regulation of actin dynamics in the hypoxia-driven local invasion
of glioblastoma cells (Figure 5U ). Severe hypoxia enhanced the
expression of cyclin G2 and SFKs and the consequent formation
of ruffles and cell migration by modulating the tyrosine phosphory-
lation of cortactin. Cyclin G2 orchestrates the recruitment to the
juxtamembrane and SFK-dependent tyrosine phosphorylation of
cortactin and thereby actin dynamics. We revealed that the SH2
or SH3 domain–binding motif and WH2 motif in cyclin G2 were
important for this mechanism. Furthermore, we also found that
cyclin G2 was a target of SFKs and phospho-cyclin G2 seemed to
prefer the actin interaction. These findings provide the first evidence
that cyclin G2 is a key regulator in the hypoxia-driven migration of
glioblastoma cells. We are now investigating the relationship between
cyclin G2 and other regulators of actin dynamics such as cdc42, rac1,
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and rhoA and the possibility that cyclin G2 affects signal transduc-
tion in which tyrosine phosphorylation is essential.
Concerning the therapeutic strategy for glioblastoma expansion,
inhibiting the hypoxia-driven local invasion is imperative. Accord-
ing to our findings, decreasing the level of cyclin G2 is sufficient
to inhibit the invasion (Figure 2, K –S ). However, the reduction
results in excessive proliferation because cyclin G2 acts as a nega-
tive regulator of the cell cycle (Figure W3, B and C ). In the mech-
anism of the local invasion in which cyclin G2–SFKs–cortactin
axis is involved, inhibiting SFKs is effective both in vitro and
in vivo, in various cells including glioma-initiating cells (Figures 4,
5, and W6). Recent studies showing that SFKs such as fyn and
src are ideal targets for glioblastoma expansion [35,36] support
our observations.
Figure 4. Cyclin G2 orchestrates cortactin tyrosine phosphorylation and the consequent migration of glioblastoma cells in concert with
SFKs. (A and B) Cyclin G2 (green) co-localizes with F-actin (red) and cortactin (blue) (A), or dynamin 2 (B) at membrane ruffles. (C) Immuno-
precipitation analysis shows that cyclin G2 interacts with endogenous cortactin and dynamin 2. (D–F) Cyclin G2 is required for the ruffle
formation in response to hypoxia and the recruitment of cortactin to the juxtamembrane in glioblastoma cells (D). U87MG cells transfected
with shRNA for human ccng2 (lower panels) show fewermembrane ruffles than control cells (upper panels) in hypoxic conditions (E). Knock-
down of cyclin G2 does not alter the expression level of cortactin (F). (G) Hypoxia induces tyrosine phosphorylation of cortactin, but not
dynamin 2, in an SFK-dependent manner. (H and I) Phosphotyrosine signals are abundant near necrotic regions, merging with cortactin (H)
and cyclin G2 (I). (J) Forced expression of cyclin G2 enhances the tyrosine phosphorylation of cortactin even under normoxic conditions.
U87MG cells were transfected with cyclin G2–EGFP or cyclin G2–V5. (K) The tyrosine phosphorylation of cortactin induced by cyclin G2 is
inhibited by dasatinib but not erlotinib. (L) Cyclin G2–enhanced wound healing is inhibited by dasatinib but not erlotinib. (M) PP2A activity
seems to have no impact on the tyrosine phosphorylation. The scale bars represent 10 μm (A), 20 μm (B, D), or 200 μm (H, I).
Neoplasia Vol. 15, No. 11, 2013 Cyclin G2 Promotes GBM Expansion Fujimura et al. 1279
Exactly why cyclin G2 determines cell behavior according to
tumor origins remains unclear. As mentioned, cyclin G2 expres-
sion is enhanced by Nodal, a member of the transforming growth
factor β superfamily. Interestingly, Nodal was recently identified as
a facilitator of glioblastoma expansion [27], whereas it inhibits car-
cinoma expansion. Moreover, in breast carcinoma, p63, a master
regulator of epithelial but not glial cell fate, is a key factor in the
expression of cyclin G2, which is controlled by transforming
growth factor β–Smad2 signaling [15]. Further studies are needed,
but the different effects of cyclin G2 on tumor expansion may
be because of signaling pathways that control carcinoma and
glioma behavior.
Figure 5. Molecular mechanism of the cyclin G2–driven tyrosine phosphorylation of cortactin and consequent invasion. (A) Immuno-
fluorescent analysis showing that c-Src is abundantly expressed in pseudopalisades and most signals overlap with signals for cyclin G2.
(B) Hypoxia significantly promotes the transcription of SFKs, Fyn, and Src in U87MG cells. (C) Cyclin G2, cortactin, and SFKs are
co-immunoprecipitated. (D) Schematic diagram of the cyclin G2 protein. Cyclin G2 has a putative SH2 domain–binding motif at the
N terminus and a noncanonical SH3 domain–binding motif (bar; 287-294) at the C terminus. Green letters indicate aliphatic amino
acids (valine, leucine, and isoleucine), and red letters indicate proline. (E) Immunoprecipitation and immunodetections in HEK293
cells transfected with cyclin G2–EGFP and Src. Cyclin G2 is tyrosine-phosphorylated in an SFK-dependent manner. (F) Deletion of
the N terminus (ΔN-G2) of cyclin G2 impairs the interaction with Src. (G and H) A single amino acid mutation (P291A) in the SH3
domain–binding motif of cyclin G2 (G2P291A) impaired the induction of cortactin tyrosine phosphorylation (G) and consequent cell
migration (H). (I–N) The P291A mutant impairs recruitment of cortactin to juxtamembrane. (O–T) Dasatinib inhibited the GBM expan-
sion enhanced by anti–vascular endothelial growth factor treatment. (U) A model describing the role of cyclin G2 in the hypoxia-driven
local invasion of glioblastoma cells. Cyclin G2 recruits cortactin to the leading edge of migrating glioma cells and promotes the
consequent tyrosine phosphorylation of cortactin, which is essential for ruffle formation and tumor invasion. The scale bars represent
200 μm (A, O–T); “nec” indicates the necrotic foci in GBM specimens.
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Figure W1. (A) Diagram of the procedure to predict the hypoxia-induced and cytoskeleton-associated proteins in human glioma cell
lines. (B) Cyclin G2 is a commonly upregulated gene in response to hypoxia among three subsets of microarray data of glioblastoma
study. (C) The expression level of cyclin G2 is correlated with hypoxia-responsive genes, ANGPTL4 and HK2, in Lausanne glioblastoma
study (Accession ID: GSE7696). (D) The ELM database predicts that cyclin G2 protein has a putative SH2 or SH3 domain–binding motif
and WH2 motif.
Figure W2. The human cyclin G2 promoter region contains putative HREs. The human cyclin G2 promoter region (−1600∼0) contains
some putative HREs (-CGTG-; red) and a FoxO3a-binding site (blue). The transcription starting site (underlined in shaded sequence) and
the translation initiating ATG (boxed) were determined according to NCBI (Accession No. NM_004354.2).
Figure W3. (A) Western blot analyses of U87MG (p53WT), U251MG (p53Mut), and LNZ308 (p53Null) cells infected with lacZ or p53 adeno-
virus. These results show that the level of p53 does not affect that of cyclin G2 and forced expression of p53 does not induce cyclin G2
expression in GBM. (B) WST-1 assay showing the effect of cyclin G2’s reduction on cell-cycle regulation in U87MG cells. (C) Cyclin G2
reduction resulted in p21 suppression.
Figure W4. Cyclin G2 is abundant in pseudopalisade-forming glioma cells. (A–C) Cyclin G2 expression in pseudopalisades is observed in
various types of GBM specimens. (D) Cyclin G2 is absent in high cellularity/high mitotic regions in GBM. The scale bars represent 10 μm
in D. “V” and “N” indicate vessel and necrosis, respectively.
Figure W5. Cyclin G2 induces the restricted tyrosine phosphorylation of cortactin in an SFK-dependent manner. (A) Ectopic expression
of cyclin G2 does not alter the total amount of tyrosine phosphorylation. (B) Dasatinib inhibits the phosphorylation induced by cyclin G2.
Note that dasatinib, but not erlotinib, decreases the peripheral signals of phosphotyrosine induced by cyclin G2. The scale bar repre-
sents 10 μm in B. (C) Cyclin G2 does not enhance transcription of SFK mRNA. (D) Exogenous cyclin G2 increases, whereas the P291A
mutant impairs, tyrosine phosphorylation signals at the juxtamembrane. The scale bar represents 10 μm in D.
Figure W6. The effectiveness of dasatinib on the expansion of glioma-initiating cells. (A) Cyclin G2 expression is enhanced in response
to hypoxia in murine glioma-initiating 005 cells. (B–D) Hypoxia stimulates the motility of 005 cells. (E) Tyrosine phosphorylation of
cortactin is enhanced in response to hypoxic stimulation in 005 cells and dasatinib attenuates it. Note that 005 cells show the phos-
phorylation in a normoxic and steady state. (F) Dasatinib attenuates the hypoxia-driven local invasion of 005 cells. Note that dasatinib
treatment inhibits the phosphorylation of src and cortactin. The scale bars represent 200 μm (F).
Figure W7. Goat anti-human cyclin G2 antibody (Santa Cruz Bio-
technology, Inc) successfully recognized ectopic cyclin G2 in
paraffin-embedded HEK293 cells that were transfected with cyclin
G2–EGFP. For other applications including immunoblot analysis,
see references. The scale bar represents 100 μm.
Figure W8. Full scans of the immunoblots shown in the figures. Boxes indicate the parts used in the figures, and numbers indicate the
molecular weights. All data were obtained with the VersaDoc Imaging System (Bio-Rad).
